Accelerate Diagnostics, Inc. Share Price

Equities

AXDX

US00430H2013

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:30:00 26/04/2024 BST 5-day change 1st Jan Change
0.9301 USD -1.61% Intraday chart for Accelerate Diagnostics, Inc. +8.28% -76.27%
Sales 2024 * 12.17M 974M Sales 2025 * 14.48M 1.16B Capitalization 20.15M 1.61B
Net income 2024 * -49M -3.92B Net income 2025 * -44M -3.52B EV / Sales 2024 * 1.66 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.39 x
P/E ratio 2024 *
-0.41 x
P/E ratio 2025 *
-0.48 x
Employees 134
Yield 2024 *
-
Yield 2025 *
-
Free-Float 62.89%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.61%
1 week+8.28%
Current month-6.05%
1 month-3.14%
3 months-27.34%
6 months-84.70%
Current year-76.27%
More quotes
1 week
0.86
Extreme 0.86
1.01
1 month
0.73
Extreme 0.73
1.05
Current year
0.73
Extreme 0.73
4.24
1 year
0.73
Extreme 0.73
11.90
3 years
0.73
Extreme 0.73
93.60
5 years
0.73
Extreme 0.73
240.00
10 years
0.73
Extreme 0.73
318.56
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 31/07/19
Director of Finance/CFO 38 31/08/17
Chief Operating Officer - 31/12/22
Members of the board TitleAgeSince
Director/Board Member 76 25/06/12
Director/Board Member 83 25/06/12
Director/Board Member 71 01/12/19
More insiders
Date Price Change Volume
26/04/24 0.9301 -1.61% 4,924
25/04/24 0.9453 +1.54% 14,119
24/04/24 0.931 -2.00% 12,785
23/04/24 0.95 +7.05% 137,870
22/04/24 0.8874 +3.31% 18,342

Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm

More quotes
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9301
Average target price
-
Consensus